Drug Type Small molecule drug |
Synonyms Buspirone/levodopa/carbidopa, Spinalon |
Mechanism 5-HT1A receptor partial agonists(Serotonin 1a (5-HT1a) receptor partial agonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), DDC inhibitors(DOPA decarboxylase inhibitors) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H16N2O5 |
InChIKeyQTAOMKOIBXZKND-PPHPATTJSA-N |
CAS Registry38821-49-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | - | - | |
Multiple Sclerosis | Phase 2 | - | - | |
Multiple Sclerosis | Phase 2 | - | - | |
Spinal Cord Injuries | Phase 2 | - | - | |
Spinal Cord Injuries | Phase 2 | - | - | |
Spinal Cord Injuries | Phase 2 | - | - |